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Abstract
Background: Breast cancer is one of the most frequent causes of death in Mexican women over
35 years of age. At molecular level, changes in many genetic networks have been reported as
associated with this neoplasia. To analyze these changes, we determined gene expression profiles
of tumors from Mexican women with breast cancer at different stages and compared these with
those of normal breast tissue samples.
Methods: 32P-radiolabeled cDNA was synthesized by reverse transcription of mRNA from fresh
sporadic breast tumor biopsies, as well as normal breast tissue. cDNA probes were hybridized to
microarrays and expression levels registered using a phosphorimager. Expression levels of some
genes were validated by real time RT-PCR and immunohistochemical assays.
Results: We identified two subgroups of tumors according to their expression profiles, probably
related with cancer progression. Ten genes, unexpressed in normal tissue, were turned on in some
tumors. We found consistent high expression of Bik gene in 14/15 tumors with predominant
cytoplasmic distribution.
Conclusion: Recently, the product of the Bik gene has been associated with tumoral reversion in
different neoplasic cell lines, and was proposed as therapy to induce apoptosis in cancers, including
breast tumors. Even though a relationship among genes, for example those from a particular
pathway, can be observed through microarrays, this relationship might not be sufficient to assign a
definitive role to Bik in development and progression of the neoplasia. The findings herein reported
deserve further investigation.
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Background
Breast cancer is one of the most frequent causes in Mexi-
can women over 35 years of age and mortality shows a
tendency to increase over time [1]. The origin and course
of sporadic breast cancer are not clear. At the molecular
level, some alterations have been reported as associated
with this neoplasia, such as changes in DNA quantity [2],
cytogenetic alterations [3], amplification of some proto-
oncogenes [4,5], loss of heterozygosity in some chromo-
somal regions [6,7], and mutations in at least four differ-
ent susceptibility genes in hereditary forms [8-11].
The traditional way of classifying breast tumors is based
on tumor size, degree of dissemination and Histopathol-
ogy. Alterations in many genetic networks are involved in
development of breast cancer; therefore, analysis of iso-
lated genes is not sufficient to adequately understand this
neoplasia. Transcriptional analysis of multiple genes
expressed by breast tumors should provide a means to
define a signature or molecular fingerprint of the disease
and might progressively replace conventional diagnostic
and prognostic parameters. Likewise, the capability to
analyze simultaneous expression levels of thousands of
genes offers better possibilities to understand and charac-
terize the complete molecular mechanisms underlying
cancer progression. Technologies such as DNA chips per-
mit integral study of the advance of the disease, with the
advantage of identifying marker genes for diagnosis, prog-
nosis, and therapy.
In several studies found correlations among expression
profiles and clinical characteristics, estrogen receptors,
lymphatic nodes or treatment response [12-16]. However,
this results can not be generalized to other populations
because development of this heterogeneous disease have
influence from multiple factors, including age, diet, genet-
ics, environment, geographic location, no pregnancy and
race [17]. To generate portraits for each population may
help in the sub-classification of tumours, prognosis, and
general understanding of breast cancer [18,19] and will
allow us to identify characteristic genes from the Mexican
population.
Tumor growth rates can be <5% of those predicted by pro-
liferation measurements alone. Several types of human
cancers such as colorectal [20], ovarian [21], endometrial
[22], and cervical [23], also showed an increase in apop-
totic index (by TUNEL assay) during tumorigenesis,
which questions if cancer research fields related with inhi-
bition of cell death might be a critical step in cancer devel-
opment. Thus, in these cases a high rate of cellular
proliferation must be responsible for tumor growth.
Human gene expression patterns derived from cDNA
microarrays have been increasingly used to identify genes
associated with human cancers [12,14,24]. On the basis
of these studies, it appears that cDNA microarray based
gene expression analysis of breast cancers tissues would
reveal molecular characteristics associated with
tumorigenesis.
Bcl-2 family proteins contain both, anti-apoptotic and
pro-apoptotic, members and are essential to maintain
organ systems. For many, but not for all apoptotic signals,
balance between these two Bcl-2 subfamilies determine
cell fate. The pro-apoptotic Bik protein is a member of one
sub-class of the Bcl-2 family designated BH3-alone [25].
The human Bik gene is located on 22q13.3 and codifies a
160 amino acid protein. Its mRNA has ubiquitous distri-
bution with elevated levels in heart and skeletal muscle
[26].
Recently, the product of Bik gene has been associated with
tumoral reversion in different cell lines and was proposed
as therapy to induce apoptosis in cancer including breast
tumors [27,28]. Using cDNA microarrays, we obtained
gene expression profiles of 15 breast cancers and 5 normal
breast tissues. Complete pairwise comparison of selected
genes with real-time RT-PCR revealed consistent overex-
pression of Bik/NBK gene in tumor samples.
Methods
Breast tissue samples
The protocol of this work was approved by the Ethical
Committee of our hospital with register number 98/718/
43 and all patients provided informed consent in signed
letter prior to the initiation of any procedure. Samples
were taken from non-affected breast tissue and affected
tissue from 15 non-related Mexican patients 40 years of
age [mean of 52 years and range 40–68 years]. All tumors
were sporadic, infiltrating, ductal adenocarcinomas from
patients who had not received adjuvant chemotherapy.
Tissues were obtained from the Oncology Hospital, at the
Centro Medico Nacional Siglo XXI of the Instituto Mexi-
cano del Seguro Social in Mexico City. Each sample was
snap-frozen in liquid nitrogen and stored at -70°C until
use. Specimens were selected for analysis by two criteria:
(i) sufficient material for analysis, and (ii) histological
evaluation by two pathologists demonstrating that sam-
ples contained at least 70% of tumor cells (in the case of
cancer samples). Representative sections from each case
were paraffin-embedded for staining with haematoxylin
and eosin to assess histopathologic diagnosis using Amer-
ican Cancer Committee criteria [29] and for their use in
Immunohistochemistry assays.
RNA extraction and mRNA purification
Total RNA of each sample was obtained with trizol and
dissolved in RNase-free water for a final concentration of
1–2 µg/µl. Samples was stored at -70°C. ConcentrationBMC Cancer 2005, 5:93 http://www.biomedcentral.com/1471-2407/5/93
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and purity of each sample was assessed by gel electro-
phoresis and spectrophotometry (Ultrospec 2000, Phar-
macia Biotech). Prior to obtaining poly A+ RNA, total
RNA was treated with DNAse I according to Atlas pure
total RNA labeling system (Clontech, Palo Alto, CA, USA).
Poly A enrichment procedure was used to obtain mRNA
(Atlas pure total RNA labeling system®, Clontech, Palo
Alto, CA, USA).
Probe labeling and hybridization
cDNA label procedure was used to obtain 32P-labeled
cDNA from 1 µg of poly A, with MoMLV reverse tran-
scriptase (Atlas pure total RNA labeling system®, Clontech,
Palo Alto, CA, USA). Labeled probes were purified with
chroma SPIN-200 columns (Atlas cDNA Expression
Arrays®, Clontech, Palo Alto, CA, USA). Incorporation of
32P into the probe was double-checked in a scintillation
counter (Beckman, model LS 9000sc).
The hybridization procedure was performed with hybrid-
ization solution mixed with the entire pool of labeled
cDNA probes with > 1.25 × 106 cpm on Atlas array mem-
brane with 609 genes, double-spotted (Atlas human can-
cer cDNA expression arrays®; Clontech, Palo Alto, CA,
USA). The membrane was hybridized at 68°C for 24 h,
and then was washed with high-to-low astringency solu-
tions. Membranes were exposed for 24 h in a phosphor
screen (Kodak storage phosphor screen, Molecular
Dynamics).
Image analysis and data collection
The digitalized image was obtained in a storm scanner
(Storm 680, Molecular Dynamics, Inc.). Expression pro-
files were obtained with Atlas image 2.0 software (Clon-
tech, Palo Alto, CA, USA) through comparison of normal
vs. tumor tissues. We used a normalization coefficient in
which average value of all genes was used to normalize the
array. This coefficient was determined with the Sum
method, which adds values of signal over background for
all genes on arrays.
Data analysis
Hybridization profiles were analyzed with J-Express pro-
gram developed and distributed by Molmine AS and col-
laborators [30], and Cluster and TreeView software's [31].
Real Time-RT-PCR analysis
The same source of total RNA used to define gene expres-
sion profiles was used in real time RT-PCR experiments,
following all instructions outlined in the LightCycler-RNA
amplification kit SYBR Green I manual (Roche Molecular
Biochemicals, Mannheim, Germany). cDNA synthesis
was carried out in LightCycler (Roche) in a capillary as fol-
lows: 20 µl mix reaction containing 500 ng of DNase I
treated total RNA, 4 µl of LightCycler-RT-PCR reaction
mix SYBR Green I (final concentration 1X), 5 mM MgCl2,
0.4 µl LightCycler-RT-PCR enzyme mix, and 5.0 pmol for-
ward and reverse primers for both genes. Bik gene primer
sequences were designed with OLIGO 4.1 and were as fol-
lows: forward 5' GAG ACA TCT TGA TGG AGA CC 3',
reverse 5' TCT AAG AAC ATC CCT GAT GT 3'. HPRT gene
primers were referred by Pieretti M et al; 1991 [32]. For
reverse transcription, the reaction was incubated at 55°C
for 30 min and at 95°C for 30 sec.
Amplification was carried out in the same capillary. Light-
Cycler was programmed as follows: 50 three-segment
cycles for amplification (10 sec at 95°C, 30 sec at 55°C,
and acquisition (single-mode), 20 sec at 72°C) and three-
segment cycle of product melting (0 sec at 95°C, 10 sec at
65°C, and 0 sec at 95°C at step-acquisition mode). Tem-
perature transition rate for all segments of amplification
cycles and melting curve cycle were set at 20°C/sec except
for segment 3 that was set at 0.1°C/sec of product-melting
curve analysis. Duplicate reactions were prepared for each
sample along with a non-template negative control (H2O
control). A standard curve was used with these assays and
LightCycler3 data analysis software (Roche Molecular Bio-
chemicals) was used in all processes.
Immunohistochemistry
For identification of Bik (NBK) protein expression,
streptavidin-biotin peroxidase complex (DAKO LSAB Kit,
Carpinteria, CA, USA) method with diaminobenzidine as
chromogen was used. Epitopes were retrieved by autoclav-
ing in 10 mM citric acid buffer, pH 6.1 for 2 min. As pri-
mary antibody, polyclonal anti-human NBK/Bik FL-160
(Santa Cruz Biotechnology, work dilution 1:100) in 1%
bovine serum albumin-phosphate buffered saline (BSA-
PBS) was used. Formalin-fixed, paraffin-embedded sec-
tions of normal skin epithelium served as positive con-
trols for Bik (NBK). Negative control slides were processed
in parallel, omitting primary antibody.
Results
Expression profiles of normal and malignant breast 
specimens
We analyzed gene expression patterns in dissected normal
or malignant human breast tissue from 20 individuals, 15
infiltrating ductal carcinomas, nine stage II, six stage III,
and five normal breast samples. Hierarchical cluster anal-
ysis was used to group genes on the basis of similarity in
their patterns of expression. We used average cluster link-
age, uncentered [31] based on Euclidean  distance and
removed all genes that were turned on in tumors but that
were not expressed in normal tissue (NCK5AI, CDK5 acti-
vator, CDC25A, ERK4, K2P, COL11A1, OBCAM,
AMPHIREGULIN, BCGF1 and BMP8).BMC Cancer 2005, 5:93 http://www.biomedcentral.com/1471-2407/5/93
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Cluster analysis of tumors and controls is described in Fig-
ure 1. Patterns of gene expression among tumors showed
great variation (Figure 1A); however, we identified two
main groups. The left branch is conformed by four histo-
logic type II and one type III, while the right branch con-
tains five type II and five type III. Left branch shows
distinctive underexpression and loss of expression areas
with genes such as IFNGR2, interleukin 2, laminin B1,
MSH2, MSH6 CASP8 and 10, RB1, PCNA, EGFR and
PGS2, among others, and a few overexpressed genes such
as MIF, CDK 2, 5, and 7, RPSA, JUP and ITGAE. On the
other hand, right branch shows overexpression areas with
genes such as CASP 10, CD30-L, and CD-40-L (TNF fam-
ily),  ras-like small, FGF 3 and 5, TDGF1, ERK5, MIF,
Dendrogram and picture of hierarchical cluster of 15 mammary tumors and normal tissue Figure 1
Dendrogram and picture of hierarchical cluster of 15 mammary tumors and normal tissue. Expression profiles 
from tumor and normal tissue (average from five normal tissues) were obtained through average-linkage, hierarchical, uncen-
tered clustering analysis, as described in Methods. Genes unexpressed in normal tissue were not included in analysis. In den-
drograms, each branch corresponds to similar expression profile among genes (A) or samples (B). Green squares in picture 
correspond to normal expression levels. Yellow squares correspond to absence of expression. Black squares correspond to 
underexpressed genes. Red squares correspond to overexpressed genes. Picture under dendrogram in panel details behavior 
of eight apoptosis-related genes along samples.BMC Cancer 2005, 5:93 http://www.biomedcentral.com/1471-2407/5/93
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IFNGR2, MIG, IFN-alpha, beta, gamma, IL-3, -4, -9 and -13,
IP-10, HPRT, DCC, TEK, netrin-2, cadherins 4, 8, 12 and 13
[33],  MMP3, 8, 10, 12 and  13  (metalloproteinase),
COL11A2, CCNG1, CDC-6, ATM, N-MYC, and p53.
In Figure 1B, tumors and controls were associated in a
dendrogram obtained with expression profile of each
sample. With this analysis, tumors were separated in two
main branches; left group contained five tumors defined
predominantly by histologic type II, while right group was
composed by stage II and III tumors, at the same percent-
age. In the lower part of the same Figure, we showed the
gene expression pattern of eight genes related with apop-
totic process obtained from each tumor, showing changes
across all samples but exposing the possible relation
between pro-apoptotic (BAK, BAX, BIK, BAD) and anti-
apoptotic genes (BCL2, BCLW, MCL1, BCL2- A1). We
showed that pro-apoptotic BCL2-interacting killer gene
(BIK/NBK) overexpressed in nearly all samples (14/15),
which makes it a possible candidate for further studies on
its role in breast cancer. MCL1  was underexpressed or
missing, at least 93.3% (14/15), relative to controls.
Due to consistent high expression of Bik gene in breast
cancer, we validated its overexpression by real-time PCR
and studied distribution of Bik protein in tumor breast
samples by Immunohistochemistry.
Real time RT-PCR assay for Bik gene
According to the Methods section, we developed real-time
RT-PCR using Bik and HPRT mRNAs as templates. In Fig-
ure 2, we showed amplification products of different sam-
ples of Bik  and  HPRT  genes. With real-time RT-PCR,
results of 9/13 samples (69%) agreed with those obtained
through microarray analysis (considering NB and T14)
and in 31% of tumors, we were unable to confirm the
result. By using melting curves (data not shown), we con-
firmed that amplification products obtained with real-
time RT-PCR were specific. As positive control, HPRT gene
(housekeeping) was used (samples numbers 11 and 14)
for tumors and normal breast (NB). We used tumor 14 as
negative control (tumor that wich show expression for Bik
gene in microarray assay).
Characterization of Bik/NBK expression by 
immunohistochemistry
After RT-PCR analysis, we checked the distribution and
abundance of Bik protein on slides obtained from the
same tissue used for histopathologic diagnosis. Only in
poorly or well-differentiated tumor areas we found pres-
ence of BIK protein with predominant cytoplasmic loca-
tion (Figure 3A). Figures 3C and 3D (magnification to
400×) show Bik protein in a sample of breast cancer. Pres-
ence of BIK protein was specific because, when primary
Real time RT-PCR validation of expression Bik and HPRT genes Figure 2
Real time RT-PCR validation of expression Bik and HPRT genes. Amplification curves of Bik (Bik T1 to T14), HPRT 
(T11 and T14) and non-affected breast (NB) mRNAs are shown. Graphic generated by LightCycler-based real time PCR ther-
mocycler. The abscissa shows fluorescence relative units and ordinate cycle number.BMC Cancer 2005, 5:93 http://www.biomedcentral.com/1471-2407/5/93
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antibody was omitted, we did not observe any signal in
neoplasic tissue (Figure 3B).
Discussion
Advances in high-density DNA microarray technology
have permitted to screen large numbers of genes and to
correlate tumoral stages and gene-expression profiles in
cancer research. The idea is that tumor behavior is ruled
by expression of hundreds of genes; thus microarrays
analysis allows those behaviors and clinical features to be
predicted. In the present study, 10 genes were turned on
in some tumors respect to the normal tissue.
With microarray analysis of samples, we identified two
subgroups probably related with cancer progression. In
the first group, we identified an underexpression area
(lower part of dendrogram in Figure 1) Wich corre-
sponded to four histological stage II tumors, (T2, T5, T12
and T14) and one tumor in histological stage III, (T3). The
latter tumor probably corresponded to a stage II tumor at
molecular level because its profile expression was similar
to others in the same group. We think that this group
belongs to an initial stage of development of neoplasia,
because it presents fewer alterations than the second
group, and because the behavior of some genes related
with the beginning of tumor development such as genes
related with DNA repairment, apoptosis, TNF, Fas-L route,
checkpoint, remodeling, and maintenance of extracellular
matrix, were underexpressed or lost their expression while
other genes were overexpressed, such as human macro-
Distribution of Bik protein in mammary ducts from adenocarcinomas Figure 3
Distribution of Bik protein in mammary ducts from adenocarcinomas. Anti-Bik/NBK polyclonal antibody) was 
reacted with HRP-secondary antibody and revealed with DAB. Haematoxylin was used as counter stain. A, C, and D are differ-
ent tumor areas. B, negative control from the same patient.BMC Cancer 2005, 5:93 http://www.biomedcentral.com/1471-2407/5/93
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phage migration inhibitory factor and some cyclin-
dependent kinases and cytoskeletal proteins.
The right branch (Figure 1) contains stage II or III tumors
and probably correspond to more advanced stages of pro-
gression of neoplasia. In this group, we found some over-
expressed genes; of these, COL11A2 and netrin-2 had not
been previously associated with breast cancer. Other
genes, such as DCC and cadherin 13, were found overex-
pressed in our samples but underexpressed in other
reports [34]; these genes probably have mutations that
differentially affect their proteins.
Apoptosis is a mechanism to control cell death which
occurs during normal development, growth, and mainte-
nance in multicellular organisms. It can be activated by
stimulation of a cell surface death receptor or release of
cytochrome c from mitochondria. In the cascade of events
initiated by this signaling, cysteine aspartyl proteases, or
caspases are cleaved from an inactive zymogen to an active
heterodimer. These active caspases degrade several com-
ponents critical for cell survival, such as DNA repair ele-
ments, structural proteins, and cell signaling peptides
[35]. Caspase-3, the primary death effector, serves as a key
target for monitoring apoptosis, for it is activated through
both cell surface death receptor and mitochondrial release
of cytochrome c [36]. Disruption in signaling pathways
that regulate apoptosis can lead to a variety of pathologic
conditions, making apoptosis an area of intense focus for
research [37].
Eight genes related with apoptosis are found in the lower
part of Figure 1B. Only two genes showed differential
expression in nearly all tumors, Bik  gene was overex-
pressed in 14/15 samples and MCL-1 gene expression was
diminished or absent in the same number of tumors. The
behavior of the remaining genes was not constant; in
tumor 5, for example, nearly all selected genes were
overexpressed, whereas in tumor 6 expression of nearly all
selected genes was lost. The heterogeneous behavior of
these genes makes it difficult to establish their role in
apoptosis or survival of neoplasic cells. However, it was
possible to establish which genes, as in the case of the Bik
gene, are probably related with cancer progression or are
involved in other genetic networks.
BH3-only proteins are structurally distant members of the
Bcl-2 protein family which triggers apoptosis. These pro-
teins share with each other and with the remainder of the
Bcl-2 family only a nine amino acid BH3 (Bcl-2 Homol-
ogy) region. This domain is required for its ability to bind
to Bcl-2-like, pro-survival proteins and to initiate apopto-
sis. Mammals have at least 10 BH3-only genes that differ
in expression pattern and model of activation (regulated
by a diverse range of transcription factors). Certain BH3-
only proteins, including Bad, Bik/Nbk, Bid, Bim/Bod, and
Bmf, are restrained by post-translational modifications
that cause their sequestration from pro-survival Bcl-2 fam-
ily members [38]. Nbk/Bik  (natural-born killer/Bcl-2-
interacting killer) is a tissue-specific BH3-only protein
which molecular function is largely unknown. Nbk fails to
induce apoptosis in the absence of Bax. Nbk interacts with
Bcl-xL and Bcl-2 but not with Bax. It was suggested that
Nbk acts as an indirect killer which triggers Bax-dependent
apoptosis, whereas Bak is not sufficient to confer sensitiv-
ity to Nbk [39].
BH3-only proteins require multidomain pro-apoptotic
members Bax and Bak to release cytochrome c from mito-
chondria and kill cells. Short peptides representing alpha-
helical BH3 domains of Bid or Bim are capable of inducing
oligomerization of Bak and Bax to release cytochrome c.
BH3 peptides from Bad and Bik cannot directly activate
Bax or Bak, but instead bind anti-apoptotic members of
BCL-2, resulting in displacement of Bid-like BH3 domains
which initiate mitochondrial dysfunction. These data sup-
port two types of BH3 domains: Bid-like domains which
activate Bax, Bak, and Bad-like domains which sensitize by
occupying the pocket of anti-apoptotic members [40].
Bik, a BH3-alone protein (Bcl-2 homology domain), is a
pro-apoptotic member of the BCL2 family. Missense Bik
gene mutations and sequence alterations in intronic
regions were observed in cell lymphomas; these data indi-
cate that mutation of the Bik gene is relatively frequent
[41,42]. The importance of phosphorylation and
desphosphorylation reactions in intracellular signaling
pathways has long been accepted. The importance of ser-
ine/threonine protein phosphatases in many processes
including apoptosis is recognized. The phosphorylation
state of anti-apoptotic (Bcl-2 and Bcl-xL) and pro-apop-
totic (Bad, Bid and Bik) Bcl-2 proteins regulates their cel-
lular activity and, therefore, cell survival and cell death.
For instance, desphosphorylation of Bad allows it to inter-
act with Bcl-xL and initiate cell death [43]. However,
mutation of the Bik phosphorylation sites, in which the
Thr and Ser residues were changed to alanine residues,
reduced the apoptotic activity of Bik protein without sig-
nificantly affecting its ability to heterodimerize with BCL-
2 [44]
Of note, a significant fraction of either ectopic or endog-
enous BIK was found associated with the endoplasmic
reticulum, suggesting that this organelle, in addition to
mitochondria, may be a target of BIK function [45]. Col-
lectively, the results identify BIK as an initiator of
cytochrome c release from mitochondria operating from a
location at the ER [46]. These results indicate that any
function of Bik in programmed cell death and stress-BMC Cancer 2005, 5:93 http://www.biomedcentral.com/1471-2407/5/93
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induced apoptosis must overlap that of other BH3-only
proteins [47].
Because the product of Bik gene is pro-apoptotic, this pro-
tein has been used to induce apoptosis in several cancer
cell lines (PC-3, HT-29, MCF-7, MDA-MB-231, 435, 468
and A540) [27,28,48]. Fay M et al; in 2003 [49] reported
underexpression of the CUL-5 gene in breast tumor tissue,
whereas expression levels in several cancer cell lines
(MCF7, MDA-MB-231) are essentially identical to those of
normal breast. Probably breast tumor tissues (i.e., Bik
gene) have a different behavior vs. breast cancer cell lines
at a molecular level. Moreover we found some reports
with different expression levels of Bik gene among multi-
ple human tissues: Daniel T et al; 1999 [48] reported
absence of Bik expression in heart, skeletal muscle, and
brain, while Verma et al; 2000 [26] reported higher expres-
sion in heart and skeletal muscle. It is difficult to reconcile
these reports.
Conclusion
It is not known whether Bik gene works as an apoptosis
activator or only sensitizes the cell for death. In any event,
it could be a prognostic factor and a possible therapy tar-
get in breast cancer. The findings reported in this paper
deserve further investigation.
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RB1 Retinoblastoma susceptibility
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